Nicole Burchett, APRN
Family · Paintsvile, KYNPI 1487207973
Payments from drug & device makers
Across 276 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$454
- Pfizer$328
- Novo Nordisk$268
- Amgen$247
- Lilly USA, LLC$217
- plus $983 from 17 others
What the payments were for
- Food & beverage$4,108100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,611 |
| GSK | 32 | $454 |
| Pfizer | 34 | $328 |
| Novo Nordisk | 17 | $268 |
| Amgen | 15 | $247 |
| Lilly USA, LLC | 14 | $217 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $200 |
| Bayer | 10 | $157 |
| Novartis | 7 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $79 |
| Boehringer Ingelheim | 4 | $65 |
| AstraZeneca | 4 | $58 |
| Johnson & Johnson | 3 | $48 |
| Dexcom, Inc. | 1 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Exact Sciences | 2 | $31 |
| Merck | 2 | $31 |
| Shield Therapeutics Inc | 1 | $26 |
| Lundbeck LLC | 1 | $20 |
| Vertex | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
How this compares
$4,108 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $151,570 |
| MounjaroTirzepatide | 78 | $89,522 |
| EliquisApixaban | 56 | $40,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $40,078 |
| UbrelvyUbrogepant | 29 | $29,101 |
| Invega SustennaPaliperidone Palmitate | 12 | $27,381 |
| JardianceEmpagliflozin | 36 | $23,738 |
| TrulicityDulaglutide | 24 | $23,311 |
| JanuviaSitagliptin Phosphate | 35 | $23,039 |
| FarxigaDapagliflozin Propanediol | 13 | $16,354 |
| Repatha SureclickEvolocumab | 19 | $15,481 |
| LinzessLinaclotide | 26 | $14,972 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $13,403 |
| QuliptaAtogepant | 11 | $11,788 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $268 | $151,570137 claims |
| Lilly USA, LLCMounjaro, Trulicity | $217 | $112,833102 claims |
| AbbVieUbrelvy, Linzess, Qulipta | $1,611 | $55,86166 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $454 | $45,25262 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr | $65 | $40,91967 claims |
| PfizerEliquis | $328 | $40,38656 claims |
| MerckJanuvia, Janumet Xr | $31 | $36,44355 claims |
| Johnson & JohnsonInvega Sustenna | $48 | $27,38112 claims |
| AstraZenecaFarxiga, Symbicort | $58 | $23,69947 claims |
| NovartisEntresto | $117 | $10,10715 claims |
| BayerKerendia | $157 | $8,37111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in Paintsvile
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.